Africa: Single-Dose Treatment for Sleeping Sickness Receives Approval

AllAfrica

February 27, 2026

Press Release - • Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness